2/13
08:12 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $38.00 price target on the stock.
Medium
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $38.00 price target on the stock.
2/10
08:00 am
jspr
Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
Medium
Report
Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
2/5
04:04 am
jspr
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference [Yahoo! Finance]
Medium
Report
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference [Yahoo! Finance]
2/4
04:30 pm
jspr
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference
High
Report
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference
1/10
08:49 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its price target lowered by analysts at HC Wainwright from $60.00 to $40.00. They now have a "buy" rating on the stock.
Low
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its price target lowered by analysts at HC Wainwright from $60.00 to $40.00. They now have a "buy" rating on the stock.
1/9
10:31 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its price target lowered by analysts at Royal Bank of Canada from $68.00 to $48.00. They now have an "outperform" rating on the stock.
Low
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its price target lowered by analysts at Royal Bank of Canada from $68.00 to $48.00. They now have an "outperform" rating on the stock.
1/6
08:44 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $70.00 price target on the stock.
Medium
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $70.00 price target on the stock.
1/6
08:00 am
jspr
Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025
Medium
Report
Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025
12/23
08:57 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $68.00 price target on the stock.
Low
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $68.00 price target on the stock.
12/6
08:06 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $63.00 price target on the stock.
Medium
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $63.00 price target on the stock.
12/2
04:30 pm
jspr
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma
Low
Report
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma